Dec. 8 at 4:11 PM
$SLS In addition to the IMMINENTLY Due Phase 3, Registrational Results for GPS Immunotherapy in AML Remission Maintenance
- Dr. Z published Updated Phase 2 Data At ASH telling the 155 Institutional Funds invested in SLS, that 009 is for getting FDA Approval.
$PFE Pfizers' - Ibrance - Palbociclib CDKinase Inhibitor
Novartis' - Kisqali -Ribociclib CDKinase Inhibitor
Eli Lilly's - Verzenio -Abemaciclib CDKinase Inhibitor
$SLS $247M Tambiciclib CDKinase Inhibitor
Bottom LINE: SLS009 / TAMBICICLIB Will Be FDA Approved and Join other Blockbuster Kinase Inhibitors:
We Know 009 only needs 25% response rates for Approval, its Plus 50% in all dose, all AML types,
- 13,400 AML-MR DXd each year.
P2a Data Updated at ASH:
- A Not Yet Met OS already more than 4X+ Longer than historical norms and No Toxicity, in treating the Most Unmet Need in AML, Post VEN HMA treatment failure dying patients who have failed all treatments with a 2.5 month life expectancy.
